Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab - Test2 - elhamkhani - TriplyDB

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

http://www.wikidata.org/entity/Q33418562

about

The Response of Macrophages and Neutrophils to Hypoxia in the Context of Cancer and Other Inflammatory Diseases Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1 Progress toward overcoming hypoxia-induced resistance to solid tumor therapy Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer Bile acids destabilise HIF-1α and promote anti-tumour phenotypes in cancer cell models Induction of cellular prion protein (PrPc) under hypoxia inhibits apoptosis caused by TRAIL treatment.Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer.Brusatol inhibits HIF-1 signaling pathway and suppresses glucose uptake under hypoxic conditions in HCT116 cells.Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.HIF-1 in cancer therapy: two decade long story of a transcription factor.Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance Targeting adipose tissue in the treatment of obesity-associated diabetes.The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.Docosahexaenoic Acid-mediated Inhibition of Heat Shock Protein 90-p23 Chaperone Complex and Downstream Client Proteins in Lung and Breast Cancer.Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer.Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.The role of tumor microenvironment in resistance to anti-angiogenic therapy.Addition of bevacizumab to systemic therapy for locally advanced and metastatic nasopharyngeal carcinoma.

P2860

Q26749138-2BE7CF47-CF2D-4411-B5CA-1537B9F744F8 Q26766240-514A5CDA-59FF-4032-B5AA-2213642CD179 Q26778957-E740DBF5-2480-40D4-975C-94BF6B8BE94E Q26796405-7C9F1A80-36AE-4FF8-9257-191111AC7CDC Q28068654-93417D67-0C70-4D51-B3EE-9EECDAD44F7B Q28596213-E27407A6-8ECB-4AF3-A488-6A910371C4D7 Q35741681-8373F987-B479-4118-A777-B654731E2F0A Q35790990-F39C32F4-C70D-4F06-A106-4A93D91CD720 Q35892646-1CDDA966-6BB5-4223-A9A7-2E597DA79AF3 Q37508566-58A7F71A-E0CC-4E39-87F8-4BB05667A42F Q38729732-22D55095-1242-41A1-8D09-8E2898999E32 Q38737693-5C6B463C-9ECE-40D9-866C-F94A6D8411EA Q38739048-DC9D8CE0-096B-4647-968A-50B65A2C70A7 Q38852204-C7428F76-68AC-4AE5-A5D3-F037049DE11C Q38910154-F3A45D43-F483-42A9-A86F-0BA8FFE29467 Q39158772-65857595-7E87-4FF9-A8A3-846606AC963B Q42317488-FAC19008-6959-4810-96DA-FDF2EED1CBF2 Q45324487-49F89266-338C-489B-9D90-500997FDD513 Q52645823-C33ED208-4B69-4FEB-B8C3-AF4330947CD1 Q55025647-0F3EFB6C-C1A2-41E0-B9FC-6F4B28BE621D

P2860

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab

http://www.wikidata.org/entity/Q33418562

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab

@ast

Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab

@en

type

label

Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab

@ast

Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab

@en

prefLabel

Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab

@ast

Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab

@en

P1433

Q33418562-8978F6CD-A732-4ABA-97A7-F8A54B51F370

P1476

Q33418562-90B72819-FC8B-4C44-BEF0-27FF06A0151F

P2093

Q33418562-14AF6EA2-E920-47A4-97A6-96A6B2AC5E53

Q33418562-32388226-0A6B-4D47-8C2B-F0019A284D57

Q33418562-3F371682-475D-4B1B-AF2E-43AC2D77D914

Q33418562-453A599C-CED2-4BA1-930F-CB2184902FD3

Q33418562-50395058-0F5F-4B37-9DC5-625FF5F7EE14

Q33418562-58C609BF-EEA0-4BEA-A136-40B222D9C124

Q33418562-80B4B7DC-E919-45D2-8FC0-A420D0DA11FC

Q33418562-8BE224B0-4A45-4B44-9C62-C011B8620E8E

Q33418562-94A976BF-45E0-4225-9041-FFFA5CAF91E6

Q33418562-CF4AFD15-4DCA-499F-9ED0-81A324CAE3CC

P2860

Q33418562-08AB60C2-E50E-412D-9EA7-07D73CE626E2

Q33418562-0BD83B18-9D0C-4B53-8E2F-BBBF0B2CEDCE

Q33418562-0ED10FC0-A23D-40AA-98B6-18EE5EB34554

Q33418562-11685C3F-1851-4F5D-A1CC-63ABBEE22509

Q33418562-1CAB7ED4-722F-4EBE-9263-C9BFEF6E8537

Q33418562-1FFF06D2-4CFD-43DB-BDE9-FE85BCC4AF41

Q33418562-2528A1A9-BCBF-4409-8834-EBDA5DAA4596

Q33418562-276FB2F2-4CE6-44AC-A8F2-170B87BE1B34

Q33418562-2858A9E0-D635-4866-B9E9-5FFA380DC30E

Q33418562-2AA345B3-8F7F-4137-969E-FA857471D251

P304

Q33418562-6D04EFB9-F25D-4EB8-8AB1-C2074370C8FB

P31

Q33418562-5522A0E8-17A5-4302-989C-819D77A20774

P356

Q33418562-359D5B35-6DAF-4990-A009-0C500A3D55A2

P407

Q33418562-6BBD2734-2A06-4D8B-A901-3B7B6269954A

P433

Q33418562-11077ACC-84D4-4A02-8EA3-F2C03D9121FC

P478

Q33418562-6938C1D3-6665-43CF-9C05-998E0AC6F579

P50

Q33418562-0AEE1BFB-889A-4B32-96F9-C14FC4F24DDC

Q33418562-E5D8143A-808D-470D-89D2-A1045B0F9A58

Q33418562-EDB0749A-6550-418D-AD67-D33DA81F6C2F

P577

Q33418562-55D5930A-AC14-47D4-92A8-619841732624

P5875

Q33418562-333B45E0-DB6C-4820-8CB4-C4CECBF64AB8

P698

Q33418562-BFDB0F1A-418C-44FA-9322-ADEEE2F77F09

P921

Q33418562-2024B270-6537-4E81-BA63-262D9F66113D

Q33418562-3F167A4C-2FFB-42C7-AD96-9FD53F1DCDB6

Q33418562-D233518A-1AB4-47CB-BA47-686C90C0CFB6

P932

Q33418562-FA06A014-9E29-48CE-9CA0-E0A466C149D0

P356

ONCOTARGET.2163

P1433

P1476

Targeting hypoxia-inducible fa ...... of bortezomib plus bevacizumab

@en

P2093

Adrienne N Howard

http://www.w3.org/2001/XMLSchema#string

Chaan S Ng

http://www.w3.org/2001/XMLSchema#string

David Hong

http://www.w3.org/2001/XMLSchema#string

Deeksha Vishwamitra

http://www.w3.org/2001/XMLSchema#string

Edward F Jackson

http://www.w3.org/2001/XMLSchema#string

Gerald S Falchook

http://www.w3.org/2001/XMLSchema#string

Hesham M Amin

http://www.w3.org/2001/XMLSchema#string

Jennifer J Wheler

http://www.w3.org/2001/XMLSchema#string

Kenneth Hess

http://www.w3.org/2001/XMLSchema#string

Kristie N Lawhorn

http://www.w3.org/2001/XMLSchema#string

P2860

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Targeting HIF-1 for cancer therapy

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases

Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Hypoxia inducible factor-1alpha as a cancer drug target

The von Hippel-Lindau tumor suppressor gene and kidney cancer

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

P304

10280-10292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2163

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267933071

http://www.w3.org/2001/XMLSchema#string

P698

25373733

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4279372

http://www.w3.org/2001/XMLSchema#string